News | December 15, 2021
NATCO Pharma to acquire Dash Pharmaceuticals
The cash consideration for the acquisition is US$ 18 million.
The cash consideration for the acquisition is US$ 18 million.
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Leaders in scientific and industrial imaging, Atik Cameras prepares for growth as Dr Panos Kapetanopoulos is promoted to DIrector of Atik Cameras Norwich, UK
It plans to add over 1000 employees over the next six months
Healtherbs helps in restoring the desired energy levels for daily activity and immunity
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
Subscribe To Our Newsletter & Stay Updated
